Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck, BMS settle patent dispute

by Lisa M. Jarvis
January 30, 2017 | A version of this story appeared in Volume 95, Issue 5

In the latest twist in the heated cancer immunotherapy arena, Merck & Co. has settled its patent dispute with Bristol-Myers Squibb and Ono Pharmaceutical over Merck’s PD1 inhibitor Keytruda. Merck will pay BMS $625 million and provide royalties on global sales of Keytruda through 2026. The deal comes a day after BMS suffered another setback with its PD1 inhibitor, Opdivo. BMS said it was no longer pursuing an accelerated approval of Opdivo combined with cancer immunotherapy agent, Yervoy, as a first-line treatment in lung cancer. In August, Opdivo failed a study as a first-line monotherapy in lung cancer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.